×
English
हिंदी
ગુજરાતી
Home
My Feed
Remove Ads
Get Premium Content
Go Pro @₹99
Loan Against Mutual Fund
Apply Now
Credit Cards
Instant Loans
Apply Now
Credit Score
Refer & Earn ₹500
Refer Now
Finance Tracker
Learning Curve
Fixed Deposits
Business Loan
Vouchers
Markets
Markets
FII & DII Activity
Corporate Action
Research Advice
Earnings
Technical Trends
Stock Deals
Intraday Large Deals
Bonds
Webinar
Pre Market
Stock Scanner
Sector Analysis
Unlisted Shares
Stock Updates
PRO Stock Lists
Monsoon Tracker
Seasonality Analysis
Crypto Dashboard
Web Stories
Tax Calculator
Forum
Gold Rate
Silver Rate
IFSC Code Finder
Storyboard18
IPO
Economic Indicators
Economic Calendar
Global Markets
US Markets
ETFs
Indian Indices
News
News
Tech/Startups
Auto
Research
Opinion
Politics
Personal Finance
EPF Guide
Real Estate
Portfolio
Watchlist
Personal Finance
Personal Finance
Loans
Fixed Deposit Comparison
Fixed Deposit Interest Calculator
Moneycontrol - SecureNow Health Insurance ratings
Mutual Funds
Mutual Funds
Performance Tracker
Top ranked funds
My Portfolio
Top performing Categories
Forum
New Fund Offers
MF Simplified
Commodities
Mutual Funds
Gold Rate
Silver Rate
Currencies
Cryptocurrency
Media
Live TV & Shows
Video
Podcast
Photos
Invest Now
Trade like Experts
Invest in Unlisted Shares
Specials
Pharma Industry Conclave
Unlocking opportunities in Metal and Mining
#MFSummit2025
Advanced Technical Charts
International
Get App
Be a
Pro
Home
PRO
Markets
News
Budget 2026
Editor’s Picks
Tech
India
Learning Curve
Portfolio
Watchlist
Commodities
MF
PF
Forum
Videos
you are here:
Home
News
Gv Prasad
Gv Prasad
Dr. Reddy’s to invest Rs 700 cr in biosimilars and API: GV Prasad on investments & AI
Dr Reddy's Q2 profit sinks 60%, US & EMs biz drag revenue 10%
New launches to drive growth in second quarter: Dr Reddy's
Will resolve issues raised by USFDA in a timely manner: DRL
Dr Reddy's gets FDA warning letter for three drug plants
Plan to revamp systems as per FDA expectations: Dr Reddy's
Dr Reddy's Q1 net up 14% at Rs 626 cr led by US & India biz
See growth over base of last year: Dr Reddy's CEO
Dr Reddy's up 2% on pact with Hetero for Hepatitis drug
Core generics, API biz to drive FY16 growth: Dr Reddy's
Likely to file 2 NDAs worth $100 m each soon: Dr Reddy's
BioAsia 2014: A holistic approach to product innovation
Delay in clinical trials approval affecting pharma sector
GV Prasad: You cannot have a company driven by one person
Dr Reddy's Lab appoints GV Prasad as chairman
Dr Reddy's Labs to acquire OctoPlus NV for euro 27.4m
Growth rates may decline in next few years: Dr Reddy's
Dr Reddy's gets USFDA ok for deep vein thrombosis injection
Union Budget 2011: India Inc assesses the math
Unsure of how biz will shape up in German mkt: Dr Reddy's
Home
Markets
Loans
SPIN
2
WIN
News
Portfolio